Prodrug designing of NSAIDs

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 124-139

  Halen, Parmeshwari K ^b   Murumkar, Prashant R ^a   Giridhar, Rajani ^a   Yadav, Mange Ram ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b Parul Institute of Pharmacy and Research   (India)

Author keywords

Amides; Esters; Inflammation; NO release; NSAIDs; Prodrugs; Prostaglandins; Ulceration

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 2 FORMYPHENYL ESTER; ACETYLSALICYLIC ACID FORMYLPHENYL ESTER; ANTIINFLAMMATORY AGENT; DICLOFENAC METHYL ESTER; DIFLUNISAL METHYL ESTER; FLUFENAMIC ACID; FLUFENAMIC ACID METHYL ESTER; IBUPROFEN; IBUPROFEN FORMYLPHENYL ESTER; INDOMETACIN; INDOMETACIN FARNESIL; INDOMETACIN FORMYLPHENYL ESTER; INDOMETACIN GLYCOLAMIDE ESTER; INDOMETACIN METHYL ESTER; INDOMETACIN MORPHOLINOALKYL ESTER; INDOMETACIN OLIGOETHYLENE ESTER; KETOPROFEN; KETOPROFEN FORMYLPHENYL ESTER; KETOROLAC; LOXOPROFEN; METOXIBUTROPATE; NAPROXEN; NAPROXEN MORPHOLINOALKYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PRODRUG; SALICYLIC ACID; SALICYLIC ACID METHYL ESTER; TOLMETIN METHYL ESTER; UNCLASSIFIED DRUG; UNINDEXED DRUG; GLYCOLAMIDE; GLYCOLIC ACID DERIVATIVE; NITROUS OXIDE;

ACUTE TOXICITY; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BEHAVIOR DISORDER; DIGESTIVE SYSTEM ULCER; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; NONHUMAN; REVIEW; STOMACH EROSION; STOMACH INJURY; STOMACH IRRITATION; STOMACH LESION; CHEMISTRY; GASTROINTESTINAL DISEASE; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG DESIGN; GASTROINTESTINAL DISEASES; GLYCOLATES; IBUPROFEN; NITROUS OXIDE; PRODRUGS;

EID: 62749201885     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709787001695     Document Type: Review

References (143)

1. Wallace, J. Non steroidal antiinflammaory drugs and gastroenteropathy: the second hundred years. Gastroenterology, 1997, 112, 1000-16.
2. Vane, J.R.; Flower, R. J; Botting, R. M. History of aspirin and its mechanism of action. Stroke, 1990, 21(Suppl): IV-12-IV-23.
3. Douthwaite, A.H.; Lintott, GAM. Gastroscopic observation of effect of aspirin and certain other substances on stomach. Lancet, 1938, 2, 1222-5.
4. Champion, G.D.; Feng, P.H.; Azuma, T; Caughey, D.E; Chan, K.H; Kashiwazaki, S.; Liu, H-C.; Nasution, A.R; Hobunaga, M.; Prichanond, S.; Torralba, T.P.; Udom, V; Yoo, M.C.; NSAID induced gastrointestinal damage. Epidemiology risk and prevention, with an evaluation of the role of Misoprostol: an Asia-Pacific perspective and consensus. Drugs, 1997, 53, 61-9.
5. Allan, H.P.; Fletcher, M. Mechanism of NSAID induced gastroenteropathy. Drugs, 1990, 40, 1-11.
6. Schoen, R.T.; Vender, R.J. Mechanism of non-steroidal antiinflammatory drug-induced gastric damage. Am. J. Med., 1989, 86, 449-58.
7. Mitchell, J.A.; Warner, T.D. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br. J. Pharmacol., 1999, 128, 1121-32.
8. Wallace, J.L.; Cirino, G. The Development of Gastrointestinal-Sparing Nonsteroidal Anti-Inflammatory Drugs. Trends Pharmacol. Sci., 1994, 15, 405-6.
9. Wallace, J.L.; Keenan, C.M.; Granger, D.N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophildependent process. Am. J. Physiol. Gastrointest. Liver Physiol., 1990, 259, G462-G467.
10. Alert, A. Chemical Aspects of Selective Toxicity. Nature, 1958, 182, 421-3.
11. Bundgaard, H. Novel chemical approaches in prodrug design. Drugs Future, 1991, 16, 443-58.
12. Bundgaard, H. The Double Prodrug Concept and its Applications. Adv. Drug Deliv. Rev., 1989, 3, 39-65.
13. Bundgaard, H. In: Design of Prodrugs; Bundgaard, H. Ed; Elsevier, New York, Plenum Press, 1986, 49-68.
14. Cioli, V.; Putzolu, S.; Rossi, V; Corradino, C. A toxicological and pharmacological study of ibuprofen guaiacol ester (AF 2259) in the rat. Toxicol. Appl. Pharmacol., 1980, 54, 332-9.
15. Paris, G.Y.; Garmaise, D.L.; Cimon, D.G. Glycerides as Prodrugs. 1. Synthesis and antiinflammatory activity of 1,3-Bis(alkanoyl)-Z-(0 -acetylsalicyloy1)glycerides (Aspirin Triglycerides). J. Med. Chem., 1979, 22, 683-7.
16. Jones, G. SCI Fine Chemicals Group and the CS Industrial Division, Medicinals Group Meeting. London. Chem. Ind., 1980, 452.
17. Paris, G.Y.; Garmaise, D.I.; Cimon, D.G.; Swett, L.; Carter, G.W.; Young P. Glycerides as Prodrugs. 3. Synthesis and Antiinflammatory Activity of [l-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetyl]glycerides (Indomethacin Glycerides) J. Med. Chem., 1980, 23, 9-12.
18. Whitehouse, M.W.; Rainsford, K.D. Esterification of acidic antiinflammatory drugs suppresses their gastrotoxicity without adversely affecting their anti-inflammatory activity in rats. J. Pharm. Pharmacol., 1980, 32, 795-6.
19. Arakawa, T.; Fukuda, T.; Nakagawa, K.; Higuchi, K.; Watanabe, T.; Tominaga, K.; Kobayashi, K. Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen Drugs Exp. Clin. Res., 1995, 21 (3), 85-8.
20. Caprariis, P.D.; Palagiano, F.; Bonina, F.; Montenegro, L.; Amico, M.D.; Ross, F. Synthesis and Pharmacological Evaluation of Oligoethylene Esters Derivatives as Indomethacin Oral Prodrugs J. Pharm. Sci., 1994, 83, 1578-81.
21. Cecchi,, R.; Rusconi, L.; Tanzi, M.C.; Danusso, F.; Ferruti, P. Synthesis and pharmacological evaluation of poly(oxyethylene) derivatives of 4-isobutylphenyl-2-propionic acid (ibuprofen) J. Med. Chem., 1981, 24, 622-5.
22. Bundgaard, H. In Bioreversible Carriers in Drug Design: Theory and Application; Roche E.B., Ed.; Pergamon Press: New York, 1987; 13-94.
23. Langer, R. New methods of drug delivery. Science, 1990, 249, 1527-33.
24. Tsunematsu, H.; Yoshida, S.; Horie, K.; Yamamoto M. Synthesis and the stereoselective enzymatic hydrolysis of flurbiprofen-basic amino acid ethyl esters. J. Drug Target, 1995, 2, 517-25.
25. Singh, P.; Hingorani, L.L.; Trivedi, G.K. Indian J. Chem., 1990, 29B (6), 551-5.
26. Neilsen, N.M.; Bundgaard, H. Evaluation of Glycolamide Esters and Various Other Esters of Aspirin as True Aspirin Prodrugs. J. Med. Chem., 1989, 32, 727-34.
27. Kahns, A.H.; Jensen, P.B.; Mork, N.; Bundgaard, H. Kinetics of hydrolysis of indomethacin and indomethacin ester prodrugs in aqueous solution. Acta Pharm. Nord., 1989, 1 (6), 327-36.
28. Venuti, M.C.; Young, J.M.; Maloney, P.J.; Johnson, D.; McGreevy K. Synthesis and biological evaluation of omega-(N,N,N-trialkylammonium) alkyl esters and thioesters of carboxylic acid nonsteroidal antiinflammatory agents. Pharm Res., 1989, 6(10), 867-73.
29. Samara, E.; Avnir,, D.; Ladkani, D.; Bialer, M. Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. Biopharm. Drug Dispos., 1995, 16, 201-10.
30. Roy, S.D.; Manoukian, E. Permeability of ketorolac acid and its ester analogs (prodrug) through human cadaver skin. J. Pharm. Sci., 1994, 83, 1548-53
31. Tamara, V.K.; Narurkar, M.M.; Crider, A.M.; Khan, M.A. Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen. Pharm. Res., 1993, 10(8), 1191-9.
32. Tamara, V. K.; Narurkar, M. M.; Crider, A. M.; Khan, M. A. Morpholinoalkyl ester prodrugs of diclofenac: Synthesis, In vitro and In vivo Evaluation. J. Pharm. Sci., 1994, 83 (5), 44-9.
33. Shanbhag, V.R.; Crider, A.M.; Gokhale, R.; Harpalani, A.; Dick R.M., Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity. J. Pharm. Sci., 1992, 81,149-54
34. Saenger, W. Cyclodextrin inclusion compounds in research and industry. Angew. Chem. Int. Ed. Engl., 1980, 19, 344-62.
35. Andersen, G.H.; Robbins, F.M.; Domingues, F.J.; Moores, R.G.; Long C.L. The utilization of schardinger dextrins by the rat. Toxicol. Appl. Pharmacol., 1983, 5, 257-66.
36. Minami, K.; Hirayama, F.; Uekama, K. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. J. Pharm. Sci., 1998, 87, 715-20.
37. Hirayama, F.; Minami, K.; Uekama, K. In-vitro evaluation of biphenylyl acetic acid-beta-cyclodextrin conjugates as colontargeting prodrugs: drug release behaviour in rat biological media. J. Pharm. Pharmacol., 1996, 48, 27-31.
38. Abordo, E.A.; Bowden, K.; Huntington, A.P.; Powell, S.L., Prodrugs. Part 3. 2-Formylphenyl esters of indomethacin, ketoprofen and ibuprofen and 6-substituted 2-formyl and 2-acylphenyl esters of aspirin. Farmaco, 1998, 53, 95-101.
39. Ogiso, T.; Iwaki, M.; Tannino, T.; Nagai, T.; Ueda, Y.; Muraoka, O.; Tanabe G. Pharmacokinetics of indomethacin ester prodrugs: gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats. Biol. Pharm. Bull., 1996, 19 (9), 1178-83.
40. Jung, Y.L.; Lee, J.S.; Kim, Y.M. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J. Pharm. Sci., 2000, 89, 594-602.
41. Wadhwa, L.K.; Sharma, P.D., Glycolamide esters of 6-methoxy-2-naphthylacetic acid as potential prodrugs - physicochemical properties, chemical stability and enzymatic hydrolysis. Int. J. Pharm., 1995, 118, 31-9.
42. Bonina, F.; Trombetta, D.; Borzi, A.; Pasquale, A.; Saija A. 1-ethylazacycloalkan-2-one indomethacin esters as new oral prodrugs: chemical stability, enzymatic hydrolysis, anti-inflammatory activity and gastrointestinal toxicity Int. J. Pharm., 1997, 156, 245-50.
43. Mahfouz, N.M.; Omar, F.A.; Aboul-Fadl T. Cyclic amide derivatives as potential prodrugs II: N-hydroxymethylsuccinimide-/isatin esters of some NSAIDs as prodrugs with an improved therapeutic index. Eur. J. Med. Chem., 1999, 34, 551-62.
44. Rautio, J.; Nevalainen, T.; Taipale, H.; Vepsalainen, J.; Gynhter, J.; Pedersen, T.; Jarvinen, T. Synthesis and in vitro evaluation of aminoacyloxyalkyl esters of 2-(6-methoxy-2-naphthyl)propionic acid as novel naproxen prodrugs for dermal drug delivery Pharm. Res., 1999, 16, 1172-8
45. Rautio, J.; Taipale, H.; Gynhter, J.; Vepsalainen, J.; Nevalainen, T.; Jarvinen, T. In vitro evaluation of acyloxyalkyl esters as dermal prodrugs of ketoprofen and naproxen. J. Pharm. Sci., 1998, 87, 1622-8.
46. Jilani, J.A.; Najib, N.M.; Ghariabeh, S.H. Synthesis and evaluation of some acyloxyethyl mefenamates as possible prodrugs. Acta Pharm. Hung., 1997, 67, 99-104.
47. Thorsteinsson, T.; Masson, M.; Loftsoson, T.; Haraldsson, G. G.; Stefansson, E. Diacyl glyceryl ester prodrugs for slow release in the skin: synthesis and in vitro degradation and absorption studies for naproxen derivatives. Pharmazie, 1999, 54, 831-6.
48. Rautio, J.; Nevalainen, T.; Taipale, H.; Vepsalaien, J.; Gynther, J.; Jarvinen, T. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur. J. Pharm. Sci., 2000, 11, 157-63.
49. Huang, Z.L.; Kagoshima, M.; Kagawa, E.; Wang, W. Q.; Shimada, H. Anti-inflammatory and ulcerogenic effects of 3-(N,Ndiethylamino) propylindometacin HCl. Zhongguo Yao Li Xue Bao, 1997, 18, 306-8.
50. Hirabayashi, H.; Tkahashi, T.; Fujisaki, J.; Masunaga, T.; Hiroi, J.; Tokunaga, Y.; Kimura, S.; Hata, T. Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS). J. Control. Release, 2001, 70, 183-91.
51. Chandrasekar, M.J.; Ravichandran, M.; Nanjan, M.J.; Suresh, B. Synthesis and evaluation of a nonsteroidal anti-inflammatory polymeric prodrug for sustained and site-specific delivery. Drug Dev. Ind. Pharm., 2001, 27, 959-64.
52. Bonina, F.; Puglia, C.; Santagati, N.A.; Saija, A.; Tomaino, A.; Tita B. Oligoethylene ester derivatives of ketoprofen, naproxen and diclofenac as oral prodrugs: a pharmacological evaluation. Pharmazie, 2002, 57, 552-5.
53. Bonina, F.P.;, Puglia, C.; Barbuzzi, T.; De Caprariis, P.; Palagiano, F.; Rimoli, M. G.; Saija A. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur. J. Pharm. Sci., 2001, 14, 123-34.
54. Khan, M.S.Y.; Khan, R.M. Synthesis and biological evaluation of glycolamide esters as potential prodrugs of some non-steroidal anti-inflammatory drugs Indian J. Chem., 2002, 41B, 2172-5.
55. Bansal, A.K.; Khar, R.K.; Dubey, R.; Sharma, A.K. Activity profile of glycolamide ester prodrugs of ibuprofen. Drug Dev. Ind. Pharm., 2001, 27, 63-70.
56. Sugimoto, M.; Kojima, T.; Asami, M.; Lizuka, Y.; Matsuda K. Inhibition of prostaglandin production in the inflammatory tissue by loxoprofen-Na, an anti-inflammatory prodrug. Biochem. Pharmacol., 1991, 42, 2363-8.
57. Khan, M.S.Y.; Khan, R.M., Synthesis of the prodrug ibuprofen β-D-gluco-pyranoside and its biological evaluation as a better moiety than the parent drug Ind. J. Chem., 2002, 41B, 1052-55.
58. Bansal, A.K.; Dubey, R.; Khar, R.K. Quantitation of Activity of Alkyl Ester Prodrugs of Ibuprofen. Drug Dev. Ind. Pharm., 1994. 20, 2025-34.
59. Bansal, A.K.; Khar, R.K.; Dubey, R.; Sharma, A.K. Alkyl ester prodrugs for improved topical delivery of ibuprofen. India J. Exp. Biol., 2001, 39, 280-3.
60. Bansal, A.K.; Khar, R.K.; Dubey, R.; Sharma, A.K. Benzyl ester prodrug of ibuprofen: pharmacological and toxicological profile. Boll. Chim. Farmaco, 2001, 140, 79-82.
61. Wang, L.F.; Chiang, H.N.; Wu, P.C. Kinetics and hydrolysis mechanism of polymeric prodrugs containing ibuprofen, ketoprofen, and naproxen as pendent agents. J. Biomater. Sci. Polymer, 2002, 13, 287-99.
62. Shaaya, O.; Magora A.; Sheskin T.; Kumar N. Anhydride prodrugs for nonsteroidal anti-inflammatory drugs. Pharm. Res., 2003, 20, 205-11.
63. Omar, F.A. Cyclic amide derivatives as potential prodrugs. Synthesis and evaluation of N-hydroxymethylphthalimide esters of some non-steroidal anti-inflammatory carboxylic acid drugs. Eur. J. Med. Chem., 1998, 33, 123-31.
64. Mahfouz, N.M.; Omar, F.A.; Aboul-Fadl, T. Cyclic amide derivatives as potential prodrugs II: N-hydroxymethylsuccinimide-/isatin esters of some NSAIDs as prodrugs with an improved therapeutic profile. Eur. J. Med. Chem., 1999, 34, 551-62.
65. Mishra, A.; Veerasamy, R.; Jain, K.P.; Dixit, V.K.; Agrawal, R.K. Synthesis, characterization and pharmacological evaluation of amide prodrugs of ketorolac. Eur. J. Med. Chem., 2008, 43(11), 2464-72.
66. Zhao, X.; Tao, X.; Wei, D.; Song, Q. Pharmacological activity and hydrolysis behavior of novel ibuprofen glucopyranoside conjugates. Eur. J. Med. Chem., 2006, 41, 1352-8.
67. Khan, M.S.Y.; Akhter, M. Synthesis, pharmacological activity and hydrolytic behavior of glyceride prodrugs of ibuprofen. Eur. J. Med. Chem., 2005, 40, 371-6.
68. Peng Yu-Shiang,; Lin Shih-Chun,; Huang Shih-Jer,; Wang Yu-Ming,; Lin Ying-Jer,; Wang Li-Fang,; Chen Jenn-Shing. Chondroitin sulfate-based anti-inflammatory macromolecular prodrugs, Eur. J. Pharm. Sci., 2006, 29, 60-9.
69. Wermuth, C.G., In; Drug Design: Fact or Fantasy? Jolles G.; Wooldridge, K.R.H.; Eds., Academic Press, London, 1984, 47-72.
70. Sinkula, A.A., In; Medicinal Chemistry, Elsevier, Amsterdam, 1977, 125.
71. Croft D.N., Cuddigan J. H. P. and Sweetland C, Gastric bleeding and benorylate, a new aspirin. Br. Med. J., 1972, 3, 545-7.
72. Alyward, M.; Holly, F.; Maddock, J.; Whelldon, M. B. Treatment of rheumatoid arthritis with tolmetin: a comparison with alclofenac. Curr. Med. Res. Opin., 1977, 4, 695-702.
73. Jones, G. Design of Prodrugs, Bundgaard, H. Ed. Elsevier Science Publishers, Amsterdam, 1985, 199.
74. Imai, T.; Fukuhara, A.; Ueda, I.; Otagiri, M. An evaluation of an anti-inflammatory-histamine H2 antagonist drug complex on gastric erosions in the rat. J. Pharmacol. Exp. Ther., 1993, 265, 328-33.
75. Ueda, I.; Ishii, K.; Arai, H.; Ikeda, S.; Hitomi, Y.; Hatanaka M. Design, synthesis and antiinflammatory activity of a new indomethacin ester. 2-[N-[3-(3-(piperidinomethyl)phenoxy)propyl] carbamoylmethylthio]ethyl 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole- 3-acetate. Chem. Pharm. Bull., 1991, 39, 679-84.
76. Halliwell, B.; Gutteridge, JMC. Chronic inflammation and the autoimmune disease. In: Halliwell B, Gutteridge JMC., (Eds.) Free radicals in biology and medicine. Oxford University Press, Oxford, 1989, 442-38.
77. Aralcon, de la Lastra; Motilva C.; Martin, LJ.; Nieto, A.; Barranco, M.D.; Cabeza, J.; Herrerias, J.M. Protective effects of melatonin on indomethacin induced gastric injury in rats. J. Pineal Res., 1999, 26, 101-7.
78. Kourounakis, P.N.; Tsiakitzis, A.P.; Galanki, D. Reduction of gastrointestinal toxicity of NSAIDs via molecular modifications leading to antioxidant anti-inflammatory drugs. Toxicology, 2000, 144, 205-10.
79. Dhaneshwar, S.S.; Chaturvedi, S.C. Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with l-tryptophan. Indian Drugs, 1994, 31, 374-80.
80. Gairola, N.; Nagpal, D.; Dhaneshwar, S.R.; Dhaneshwar, S.S.; Chaturvedi, S.C., Synthesis, hydrolysis Kinetics and pharmacodynamic profile of novel prodrugs of flurbiprofen. Indian J. Pharm. Sci., 2005, 67, 369-73.
81. Bhosale, A.V.; Agarwal, G.P.; Mishra, Preparation and characterization of mutual prodrugs of ibuprofen. Indian J. Pharm. Sci., 2004, 66, 158-63.
82. Sharma, V.; Khan, M.S.Y. Prodrugs and mutual prodrugs: Synthesis of some new pyrazolone and oxadiazole analogues of few nonsteroidal anti-inflammatory drugs. Pharmazie, 2003, 2, 99-103.
83. Sheha, M.; Khedr, A.; Elsherief, H. Biological and metabolic study of naproxen-propyphenazone mutual prodrug. Eur. J. Pharm. Sci., 2002, 17, 121-30.
84. Fadl, T.A.; Omar, F.A. Paracetamol (acetaminophen) esters of some non-steroidal anti-inflammatory carboxylic acids as mutual prodrugs with improved therapeutic index. Inflammopharmacology, 1998, 6, 43-57.
85. Galanakis, D.; Kourounakis, A.P.; Tsiakitzis, K.C.; Doulgkeris, C.; Rekka, E.A.; Gavalas, A.; Kravaritou, C.; Charitos, C.; Kourounakis, P.N. Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity. Bioorg. Med. Chem. Lett., 2004, 14, 3639-43.
86. Christos, M.; Doulgkeris, C.M.; Galanakis, D.; Kourounakis, A.P.; Tsiakitzis, K.C.; Gavalas, A.M.; Eleftheriou, P.T.; Panagiotis, Victoratos, P.; Eleni, A.; Rekka, E.A.; Kourounakis, P.N. Synthesis and pharmacochemical study of novel polyfunctional molecules combining anti-inflammatory, antioxidant, and hypocholesterolemic properties. Bioorg. Med. Chem. Lett., 2006, 16, 825-9.
87. Yadav, M.R.; Nimekar, D.M.; Ananthakrishnan, A.; Brahmkshatriya, P.S.; Shirude, S.T.; Giridhar, R.; Arvind Parmar, A.; Balaraman, R. Synthesis of new chemical entities from paracetamol and NSAIDs with improved pharmacodynamic profile. Bioorg. Med. Chem. Lett., 2006, 14, 8701-6.
88. Vane, J.R.; Botting, R.M. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res., 1995, 44, 1-10.
89. Fu, J.Y.; Masferrer J.L.; Seibert K.; Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cycloxygenase) in human monocytes. J. Biol. Chem., 1990, 265, 16737-40.
90. Maseferrer, J.L.; Zweifel B.S.; Seibert K.; Needleman, P. Selective regulation of cellular cycloxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest., 1990, 86, 1375-80.
91. Harris, R.C.; McKanna, J.A.; Akai, Y.; Jacobson, H.R.; Dubois, R.N.; Breyer; M.D. Cycloxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest., 1994, 94, 2504-10.
92. Kargman, S.; Charlson, S.; Cartwright, M.; Frank, J.; Reindeau, D.; Mancini, J.; Evans, J.; Neill, G. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tract. Gastroenterology, 1996, 111, 445-54.
93. Zarghi, A.; Rao, P.N.P.; Knaus, E.E. Synthesis and biological evaluation of methanesulfon- amide analogues of rofecoxib: Replacement of methanesulfonyl by methanesulfonamido decreases cyclooxygenase-2 selectivity. Bioorg. Med. Chem., 2006, 15, 1056-61.
94. Zarghi, A.; Arfaee, S.; Rao, P.N.P.; Knaus, E.E. Design, synthesis, and biological evaluation of 3-diarylprop-2-en-1-ones: A novel class of cyclooxygenase-2 inhibitors. Bioorg. Med. Chem., 2006, 14, 2600-5.
95. Block, W.C.; Baylyl, C.; Belley, M.; Chan, C.C.; Charleson, S.; Denis, D.; Gauthier, J.Y.; Gordon, R.; Guay, D.; Kargman, S. From indomethacin to a selective COX-2 inhibitor: Development of indo-138 lalkanoic acids as potent and selective cyclooxygenase-2 inhibitors Biorg. Med. Chem. Lett., 1996, 6, 725-30.
96. Leblanc, Y.; Black, W.C.; Chan, C.C.; Delroe, D.; Denis, D.; Grimm, B.L.; Gauthier, J.Y.; Gordon, R.; Guay, D. Synthesis and biological evaluation of both enantiomers of L-761,000 as inhibitors of cyclooxygenase 1 and 2. Biorg. Med. Chem. Lett. 1996, 6, 731-36.
97. Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M.P. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol., 1996, 3, 927-33.
98. Kalgutkar, A.S.; Crews, B.C.; Rowinson, S.W.; Garner, C.; Seibert, K.; Marnett, L.J. Aspirin-Like Molecules that Covalently Inactivate Cyclooxygenase-2. Science, 1996, 280, 1268-70.
99. Kalgutkar, A.S.; Kozak, K.R.; Crews, B.C.; Rowinson, S.W.; Hoehgesang, G.P.; Marnett, L.J. Covalent Modification of Cyclooxygenase-2 (COX-2) by 2-Acetoxyphenyl Alkyl Sulfides, a New Class of Selective COX-2 Inactivators. J. Med. Chem., 1998, 41, 4800-18.
100. Baylyl, C.; Black, W.C.; Leger, S.; Quimet, N.; Quellet, M.; Pereival, M.D. Structure-based design of COX-2 selectivity into flurbiprofen. Biorg. Med. Chem. Lett., 1999, 9, 307-12.
101. Wallace, J.L. Gastric ulceration: critical events at the neutrophilendothelium interface Can. J. Physiol. Pharmacol., 1993, 71, 98-102.
102. Wallace, J.L.; and Del Soldato, P. The therapeutic potential of NONSAIDs. Fundam. Clin. Pharmacol., 2003, 17, 11-20.
103. Elliott, S.N.; McKnight, W.; Cirino, G.; Wallace, J.L.; A chronic nitric oxide releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology, 1995, 109, 524-30.
104. Fujihara, C.K.; Nitroflurbiprofen, a new non-steroidal anti-inflammatory, ameliorates structural injury in remnant kidney. Am. J. Physiol., 1998, 274 (Renal Physiol. 43): F573-F579, 1998.
105. Del Soldato, P.; Sorrentino, R.; Pinto, A. NO-aspirins, a class of new-inflammatory and anti-thrombotic agents. Trends Pharmacol. Sci., 1999, 20, 319-23.
106. Takeuchi, K.; Ukawa, H.; Konaka, A.; Kitamura, M.; Sugawa, Y. Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin. J. Pharmacol. Exp. Ther., 1998, 286, 15-21.
107. Al-Swayeh, O.A.; Clifford, R.H.; Del Soldato P.; Moore P.K. A comparison of the antiinflammatory and antinociceptive activity of nitroaspirin and aspirin. Br. J. Pharmacol., 2000, 129, 343-50.
108. Wallace, J.L.; Muscara, M.N.; McNight, W.; Dicay, M.; Del Soldato P.; Cirino G. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX 4016. Thromb. Res., 1999, 93, 43-50.
109. Momi, S.; Emerson, M.; Paul W.; Leone M.; Mezzasoma A.M.; Del Soldato P. Prevention of pulmonary thromboembolism by NCX4016, a nitric oxide-releasing aspirin. Eur. J. Pharmacol., 2000, 397, 177-85.
110. Wallace, J.L.; McNight, W.; Baydoun, A.R.; Cirino, G. Antithrombotic effects of a nitric oxide-releasing, gastricsparing aspirin derivative. J. Clin. Invest., 1995, 96, 2711-8.
111. Takeuchi, K.; Ukawa, H.; Konaka, A.; Kitamura, M.; Sugawa, Y. Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin. J. Pharmacol. Exp. Ther., 1998, 286, 115-21.
112. Napoli, C.; Aldini, G.; Wallace, J.L.; Maffei, R.; Lerman, L.O..; Ignarro L.J. Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc. Natl. Acad. Sci. USA, 2000, 99, 1689-94.
113. Tagliaro, F.; Cuzzolin, L.; Adami, A.; Scarcella, D.; Crivellente, F.; Benoni, G. Pharmacokinetics of a new nitroderivative of acetylsalicylic acid after a single dose in rats. Life Sci., 1997, 60, 101-6.
114. Wallace, J.L.; McKnight, W.; Wilson, T.L.; Del Soldato, P.; Cirino, G. Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils. Am. J. Physiol. Gastroenterol. Liver Physiol., 1997, 273, G1246-1251.
115. Tashima, K.; Fujita, A.; Umeda, M.; Takeuchi, K. Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats. Life Sci., 2000, 67, 1639-52.
116. Gilmer, J.F.; Moriarty, L.M.; McCafferty, D.F.; Clancy, J.M. Synthesis, hydrolysis kinetics and antiplatelet effects of isosorbide mononitrate derivatives of aspirin. Eur. J. Pharm. Sci., 2001, 14, 221-7.
117. Bandarage, U.K.; Chen, L.; Fang, X.; Garvey, D.S.; Glavin, A.; David, R.; Janero, L.; Gordon L.; Mercer, G.J.; Saha, J.K.; Schroeder, J.D.; Shumway, M.J.; William, S.T. Nitrosothiol esters of diclofenac synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J. Med. Chem., 2000, 43, 4005-16.
118. Janero, D.R. Nitric oxide-related pharmaceuticals: contemporary approaches to therapeutic NO modulation. Free Radic. Biol. Med., 2000, 28, 1495-506.
119. Marshall, M.; Moore, P.K. Effect of nitric oxide releasing paracetamol and flurbiprofen on cytokine production in human blood. Eur. J. Pharmacol., 2004, 483, 317-22.
120. Rigas, B.; Kashfi, K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med., 2004, 10, 324-30.
121. Hoogstraate, J.; Andersson L.I.; Berge O.G.; Jonzon B.; Ojteg G. COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation. Inflammopharmacology 2003, 11, 423-8.
122. Whittle, BJ.R. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur. J. Pharmacol., 2004, 500, 427-39.
123. Jonzon, B.; Bjarnason, I.; Hawkey, C.; Jones, J.; Goddard, A.; Fagerholm, U.; Karlsson, P. The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers. Inflammopharmacology, 2003, 11, 437-44.
124. Cena, C.; Lolli, M.L.; Lazzarato, L.; Guaita, E.; Morini, G.; Coruzzi, G.; McElroy, S.p.; Megson, I.L.; Fruttero, R.; Gasco, A. Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin, J. Med. Chem., 2003, 46, 747-54.
125. Carlos, A.; Velazquez, P.N.; Rao, P.; Knaus E.E. Novel Nonsteroidal Antiinflammatory Drugs Possessing a Nitric Oxide Donor Diazen-1-ium-1,2-diolate Moiety: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies. J. Med. Chem., 2005, 48, 4061-7.
126. 2-Acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): Synthesis, nitric oxide release, and biological evaluation studies Bioorg. Med. Chem., 2007, 15, 4767-74.
127. Ranani, R.R.; Michael, E. Synthesis and anti-inflammatory activity of a series of N-substituted naproxen glycolamides: Nitric oxide-donor naproxen prodrugs Bioorg. Med. Chem., 2006, 14, 2589-99.
128. Downing, J.E.G.; Madden, J. C.; Ingram, M.J.; Rostron, C. Gastric and thymic assay of acute oral treatment of rats with nitric oxide esters of ibuprofen or indomethacin Biochem. Biophys. Res. Commun., 2005, 334, 646-53.
129. Ellis, J. L.; Augustyniak M.E.; Cochran E D; Earl, R. A.; Garvey, D.S.; Gordon, L.J.; Janero, D.R.; Khanapure, S.P.; Letts, L.G.; Melim T.L; Murty M. G.; Schwalb D. J.; Shumway M. J.; Selig, W. M.; Trocha, A.M.; Young, D. V.; Zemtseva, I.S.; James, E.; NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology, 2004, 12, 521-34.
130. Takeuchi, K.; Mizoguchi, H.; Araki, H.; Komoike, Y.; Suzuki, K. Lack of gastric toxicity of nitric oxide-releasing indomethacin, NCX-530, in experimental animals. Dig. Dis. Sci., 2001, 46, 1805-18.
131. del Soldato, P.; Sorrentino, R.; Pinto, A. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol. Sci., 1999, 20, 319-23.
132. Kaza, C.S.; Kashfi, K.; Rigas, B. Colon cancer prevention with NOreleasing NSAIDs. Prostaglandins Other Lipid Mediat., 2002, 67, 107-20.
133. Fiorucci, S.; Santucci, L.; Gresele, P.; Faccino, R.M.; Del Soldato, P.; Morelli, A.; Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology, 2003, 124, 600-7.
134. Yeha, R.K.; Chena. J.; Williamsa, J.L.; Balucha, M.; Hundleya T. R,. Rosenbauma R. E, Kalalaa S, Traganosb F, Benardinic F., Soldatoc P, Kashfid, K.; Rigasa, B.; NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem. Pharmacol., 2004, 67, 2197-205.
135. Fiorucci, S.; Antonelli, E.; Distrutti, E,; Rizzo, G.; Mencarelli, A.; Orlandi, S.; Zanardo, R.; Renga, B.; Di Sante M.; Morelli, A.; Cirino, G.; Wallace, J.L. Gastroenterology, 2005, 129, 1210-24.
136. Wallace, J.; Cirino, G.; Santagada, V.; Caliendo, G.; United States Patent, Hydrogen sulphide derivatives of Non-steroidal antiinflammatory drugs. US 2008/0004245 A1, Jan 3 2008.
137. Yanagawa, A.; Fukumura, T.; Matsui, H.; Uemura, H.; Endo, T.; Nakagawa, T.; Mizushima, Y. Possible mechanisms of gastroduodenal mucosal damage in volunteers treated with nonsteroidal antiinflammatory drugs-the usefulness of prodrugs. J. Rheumatol., 1992, 19, 1075-82.
138. Halen, P.K.; Chagti, K.K.; Giridhar, R.; Yadav, M.R. Synthesis and Pharmacological Evaluation of Some Dual-Acting Aminoalcohol Ester Derivatives of Flurbiprofen and 2-[1,1'-Biphenyl-4-yl]acetic Acid: A Potential Approach to Reduce Local Gastrointestinal Toxicity. Chem. Biodiver., 2006, 3, 1238-47.
139. Halen, P.K., Raval M.K., Chagti, K.K., Giridhar, R., Yadav, M.R. Synthesis and evaluation of some gastrointestinal sparing antiinflammatory aminoethyl ester derivatives of naphthalene based NSAIDs. Arch. Pharm., 2007, 340, 88-94.
140. Yadav, M.R.; Halen, P.K.; Chagti, K.K.; Hemalata, B.; Giridhar, R. A novel approach towards therapeutic optimization of diclofenac. Ars. Pharm., 2005, 46, 263-77.
141. Halen, P.K.; Yadav, M.R.; Chagti, K.K.; Reshmi, C.S.; Giridhar, R. Synthesis and evaluation of dual acting esters of aspirin and ketorolac. Arch. Pharm., 2006, 47, 61-79.
142. Halen, P.K.; Chagti, K.K.; Giridhar, R.; Yadav, M.R. Substituted aminoalcohol ester analogs of indomethacin with reduced toxic effects. Med. Chem. Res., 2007, 16, 101-11.
143. Halen, P.K.; Chagti, K.K.; Giridhar, R.; Yadav, M.R. Combining Anticholinergic and Anti-inflammatory Activities into a Single Moiety: A Novel Approach to Reduce Gastrointestinal Toxicity of Ibuprofen and Ketoprofen. Chem. Biol. Drug Des., 2007, 70, 450-5.